Reuters logo
BRIEF-Rovi to begin registration of its biosimilar enoxaparin in Europe
March 7, 2017 / 7:30 AM / 7 months ago

BRIEF-Rovi to begin registration of its biosimilar enoxaparin in Europe

March 7 (Reuters) - Laboratorios Farmaceuticos Rovi SA:

* Completes marketing authorization request procedure of its biosimilar enoxaparin in 26 European Union (EU) countries

* To begin registration phase of its heparin compound in EU

* National registration phase expected to last 3-10 months Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below